1, 2025, or on the plan sponsor's 2025 renewal date
Available in English and Spanish, the platform gives researchers, students and other users unrestricted access to its calculators, formula guides and educational resources

Ro exited compounded GLP-1s in 2026 amid FDA enforcement pressure on the category Brand-name Wegovy oral pill (FDA-approved semaglutide) $149/month first month, rising to $199$299/month at higher ongoing doses Brand-name Wegovy injection/pen (FDA-approved) $199/month first month, rising to $199$399/month ongoing Brand-name Zepbound KwikPen (FDA-approved tirzepatide) $299/month first month, rising to $399$449/month ongoing Brand-name Ozempic (FDA-approved semaglutide for type 2 diabetes) insurance-dependent pricing (not independently verified this sweep) Important compliance note on compounded products Compounded semaglutide and compounded tirzepatide whether obtained through Cora Health or other telehealth platforms that offer compounded medication are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products (Ozempic, Wegovy, Mounjaro, Zepbound)

The SmPC notes that injectable semaglutide has not shown clinically relevant effects on the absorption of tested oral medicines, and routine dose adjustments are not required
Volume 88, Issues 1112, 14 March 2011, Pages 535-542 Chang, C.-H., Tsai, W.-C., Lin, M.-S., Hsu, Y.-H., & Pang, J.-H